share_log

騰盛博藥-B：自願性公告 任命首席科學官

BRII-B: VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF SCIENTIFIC OFFICER

香港交易所 ·  Jan 3 20:00
Summary by Futu AI
腾盛博药-B（Brii Biosciences Limited）於2024年1月3日宣布任命Brian Alvin Johns博士為公司首席科學官。Johns博士將負責新藥開發項目及制定公司未來的策略和優先事項。他在製藥行業擁有豐富經驗，曾在HemoShear Therapeutics, Inc.及ViiV Healthcare Limited等公司擔任要職，並在葛蘭素史克公司有顯著貢獻。腾盛博药董事長兼首席執行官Zhi Hong博士對Johns博士的加入表示歡迎，認為其豐富經驗將為公司帶來助益。Johns博士也對於加入腾盛博药表示期待，並希望為感染性疾病的治療開發貢獻力量。
腾盛博药-B（Brii Biosciences Limited）於2024年1月3日宣布任命Brian Alvin Johns博士為公司首席科學官。Johns博士將負責新藥開發項目及制定公司未來的策略和優先事項。他在製藥行業擁有豐富經驗，曾在HemoShear Therapeutics, Inc.及ViiV Healthcare Limited等公司擔任要職，並在葛蘭素史克公司有顯著貢獻。腾盛博药董事長兼首席執行官Zhi Hong博士對Johns博士的加入表示歡迎，認為其豐富經驗將為公司帶來助益。Johns博士也對於加入腾盛博药表示期待，並希望為感染性疾病的治療開發貢獻力量。
Brii Biosciences Limited announced on January 3, 2024 the appointment of Dr. Brian Alvin Johns as Chief Scientific Officer of the Company. Dr. Johns will be responsible for new drug development projects and formulating the company's future strategies and priorities. He has extensive experience in the pharmaceutical industry, having held key positions at companies such as HemoShear Therapeutics, Inc. and **** Healthcare Limited, and has made significant contributions to Glenshek. Dr. Zhi Hong, Chairman and CEO of Teng Sheng Bo Pharmaceuticals, welcomed the addition of Dr. Johns, believing that his extensive experience will benefit the company. Dr. Johns is also excited about joining the drug Tenzheng and hopes to contribute to the development of treatments for infectious diseases.
Brii Biosciences Limited announced on January 3, 2024 the appointment of Dr. Brian Alvin Johns as Chief Scientific Officer of the Company. Dr. Johns will be responsible for new drug development projects and formulating the company's future strategies and priorities. He has extensive experience in the pharmaceutical industry, having held key positions at companies such as HemoShear Therapeutics, Inc. and **** Healthcare Limited, and has made significant contributions to Glenshek. Dr. Zhi Hong, Chairman and CEO of Teng Sheng Bo Pharmaceuticals, welcomed the addition of Dr. Johns, believing that his extensive experience will benefit the company. Dr. Johns is also excited about joining the drug Tenzheng and hopes to contribute to the development of treatments for infectious diseases.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.